Clinical Trial Update: Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating biomarkers of sensitivity and resistance to nivolumab plus ipilimumab in advanced non-small cell lung cancer, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Advanced Stage Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-05-29